Weed Week: Cannabis-feed for chickens and cannabis campaigner nabs Queen’s Birthday honour
Pic: Darshh / iStock / Getty Images Plus via Getty Images.
- A Thai university says adding cannabis to chicken feed has positive results on meat and egg quality
- Aussie cannabis campaigner now a Member of the Order of Australia
- MGC Pharma’s CBD treatment proves effective against brain tumors
Chiang Mai University in Thailand has been studying the effects on chickens when cannabis was mixed into their feed or water – and so far the results are looking positive.
It might even be an opportunity to reduce farmers’ dependence on antibiotics.
Chiang Mai University’s department of animal and aquatic sciences assistant professor Chompunut Lumsangkul said cannabis-supplemented chickens tended to experience fewer cases of avian bronchitis, and the quality of their meat – judged by the composition of protein, fat and moisture, as well as its tenderness – was also superior.
“At the level of intensity we gave them, it wouldn’t get the chickens high,” she said.
“I try to find the suitable level for them that could help them to improve immunity and performance without any bad effects.”
There are no traces of cannabinoids in the chicken meat or its egg, but more research is needed – with Chompunut yet to publish her results.
Cannabis campaigner nabs Queen’s Birthday honour
Barry Lambert has had a Member of the Order of Australia to his name for his service to cannabinoid medical research, business, and to charitable organisations.
Lambert co-founded the Lambert Initiative for Cannabinoid Therapeutics at University of Sydney with a A$33.7m donation in 2015 after his granddaughter’s symptoms from Dravet Syndrome – a severe form of epilepsy – improved with the use of cannabidiol.
He also co-founded the Lambert Center for the Study of Medicinal Cannabis and Hemp, at Thomas Jefferson University, in Pennsylvania, USA and the medicinal cannabis advocacy group Greenlight Project in 2017.
ASX WEED STOCKS
| Code | Company | Price | % Year | % Six Month | % Month | % Week | Market Cap |
|---|---|---|---|---|---|---|---|
| ECS | ECS Botanics Holding | 0.022 | -50% | -21% | -8% | 16% | $18,814,421.34 |
| IRX | Inhalerx Limited | 0.077 | -27% | 3% | -9% | 3% | $12,466,554.82 |
| DTZ | Dotz Nano Ltd | 0.32 | -13% | -22% | 7% | 2% | $145,211,452.32 |
| CAU | Cronos Australia | 0.265 | 141% | 29% | -5% | 0% | $143,162,608.94 |
| CTV | Colortv Limited | 0.007 | -94% | -86% | -36% | 0% | $1,082,361.94 |
| WFL | Wellfully Limited | 0.055 | 4% | -29% | -26% | 0% | $14,880,812.65 |
| HGV | Hygrovest Limited | 0.064 | -30% | 0% | 7% | 0% | $14,717,055.04 |
| SCU | Stemcell United Ltd | 0.014 | -18% | 0% | 0% | 0% | $14,696,980.89 |
| MRG | Murray River Grp | 0.245 | 53% | 0% | 0% | 0% | $10,808,210.04 |
| TSN | The Sust Nutri Grp | 0.14 | -67% | -43% | 4% | 0% | $16,884,893.90 |
| RGI | Roto-Gro Intl Ltd | 0.011 | -75% | -42% | 0% | 0% | $3,768,520.77 |
| PAL | Palla Pharma Ltd | 0.295 | -17% | 0% | 0% | 0% | $47,764,383.09 |
| EVE | EVE Health Group Ltd | 0.001 | -76% | -70% | -20% | 0% | $4,309,808.56 |
| AC8 | Auscann Grp Hlgs Ltd | 0.045 | -61% | -47% | -26% | -4% | $19,824,619.95 |
| LGP | Little Green Pharma | 0.29 | -56% | -55% | -9% | -8% | $62,469,360.46 |
| CGB | Cann Global Limited | 0.021 | -83% | -58% | -19% | -9% | $4,918,597.58 |
| MXC | Mgc Pharmaceuticals | 0.016 | -67% | -58% | -27% | -11% | $46,380,995.48 |
| AVE | Avecho Biotech Ltd | 0.014 | -13% | -7% | -22% | -13% | $25,729,375.36 |
| BOT | Botanix Pharma Ltd | 0.063 | -9% | 13% | -18% | -13% | $60,334,808.59 |
| MDC | Medlab Clinical Ltd | 0.062 | -62% | -57% | -29% | -13% | $20,872,715.93 |
| CAN | Cann Group Ltd | 0.27 | -33% | -5% | -17% | -13% | $96,008,969.38 |
| LV1 | Live Verdure Ltd | 0.18 | -14% | -55% | -18% | -14% | $7,571,578.50 |
| NTI | Neurotech Intl | 0.055 | 2% | -7% | 0% | -15% | $40,466,549.31 |
| RNO | Rhinomed Ltd | 0.135 | 1% | -51% | -21% | -16% | $37,143,560.22 |
| ZLD | Zelira Therapeutics | 0.97 | -88% | -83% | -23% | -16% | $9,289,802.52 |
| EOF | Ecofibre Limited | 0.245 | -72% | -57% | -34% | -17% | $94,224,750.66 |
| CPH | Creso Pharma Ltd | 0.0415 | -77% | -50% | -17% | -17% | $54,444,285.08 |
| WOA | Wide Open Agricultur | 0.56 | -43% | -24% | -4% | -17% | $78,196,981.53 |
| BOD | BOD Australia | 0.08 | -78% | -64% | -43% | -18% | $8,783,385.36 |
| IHL | Incannex Healthcare | 0.285 | 6% | -41% | -38% | -20% | $345,330,626.67 |
| EMD | Emyria Limited | 0.2 | 5% | -46% | -26% | -20% | $48,125,432.08 |
| IDT | IDT Australia Ltd | 0.11 | -61% | -77% | -15% | -21% | $30,127,724.63 |
| ALA | Arovella Therapeutic | 0.023 | -43% | -43% | -37% | -23% | $14,736,374.97 |
| AGH | Althea Group | 0.07 | -79% | -70% | -46% | -26% | $22,120,341.53 |
| EXL | Elixinol Wellness | 0.024 | -83% | -70% | -47% | -27% | $7,590,373.70 |
| EPN | Epsilon Healthcare | 0.023 | -85% | -72% | -21% | -32% | $5,768,496.19 |
| ROO | Roots Sustainable | 0.003 | -75% | -40% | -40% | -33% | $2,623,714.41 |
Only three companies were in the green, with 10 companies flat and 24 stocks in the red.
Here are the ones with notable news:
The company’s three-year pre-clinical in-vitro research into the use of cannabinoids in the treatment of glioblastoma, a fast-growing and aggressive form of brain tumour, has delivered outstanding results – reducing the cells’ viability and inducing caspase-dependent cell apoptosis (or cell death).
Tests conducted on the glioblastoma biopsy samples demonstrated that the CBD/CBG treatment’s efficacy was not enhanced by the addition of a widely used chemotherapy treatment, which has been linked to adverse events.
“The results of this trial are enormously exciting both for the company, and for the treatment of fatal cancerous tumours,” co-founder and MD Roby Zomer said.
“MGC Pharma’s research has demonstrated the effect of naturally derived cannabinoid products on stage IV brain tumours without the use of toxic chemotherapy components.
“We are proud of the work achieved thus far and are looking forward to advancing our proprietary formulation to the next stage of clinical trials.”
MGC Pharma plans to undertake additional research to further demonstrate the formulation’s efficacy as a treatment for glioblastoma.
ECS has revamped its strategy to focus business and maximise growth, seeking to divest its Tasmanian operation and focus on growth through its Victorian facilities, which cater to the rapidly growing medicinal cannabis market.
Given the increasing demand profile of medicinal cannabis dry flower, ECS’ board and management have concluded that the company should focus on growing the Victorian operation and increasing dry flower cultivation and manufacturing on-site. The reduction in planned cultivation from Tasmania will be replaced by increasing cultivation at the Victorian facility.
ECS is confident that this will deliver streamlined operations and expedited sales growth and has lodged an application with the Office of Drug Control to double the size of the cultivation footprint at the Victorian site and expects to expand into this area in the coming season.
The company will also implement a realignment of its board and management to underpin the transition.
The company recently reported significant development in the preclinical research of its lead asset program, NTI164 – a proprietary cannabis strain that contains high levels of unique minor cannabinoids and less than 0.3% THC, exclusively licensed from Dolce Cann Global.
Preclinical studies conducted in human neuronal cells have demonstrated that NTI164, when combined with Diclofenac (the pharma ingredient found in Voltaren), significantly reduced and normalised the levels of key inflammatory biomarkers.
These key biomarkers/cytokines are associated with the onset and development of multiple neuro-inflammatory disorders, including multiple sclerosis (MS) and Alzheimer’s disease.
Diclofenac, when used alone, had a significantly lesser effect on these markers, but when combined with NTI164, Diclofenac’s effect was significantly enhanced, showing a 93% reduction in the expression of TNF-alpha, 80% reduction in the expression of IL-6, as well as 38%-66% reduction in other key biomarkers.
“The potential to create combination treatments with NTI164 plus Diclofenac or Prednisone that increases efficacy and significantly reduces side effects is now a major driver for the company,” said chairman of Neurotech, Brian Leedman.
“Given the impending release of our final ASD study results, the company is well and truly positioned for an extremely busy second half to the year as we move to secure strategic partners and undertake further clinical trials given our results to date.”
The cannabis company says results of longitudinal, real-world data (RWD) from 94 patients using ZENIVOL supports its effectiveness as a therapeutic option to manage chronic insomnia symptoms.
In the study, ZENIVOL reduced the Insomnia Severity Index (ISI) scores from 19.5 (Moderate clinical insomnia) to 14.3 (Subthreshold insomnia).
Zelira also announced that its enhanced distillate capture and dissolution matrix (EDCDM) Technology licence agreement with DRCN Holdings LLC (DRCN) has now been terminated.
On 10 January 2022, Zelira received US$250,000 of the US$1,000,000 upfront, non-refundable, non-contingent licensing fee due from DRCN.
And the company has now received an additional $250,000 payment from DRCN, for a total receipt of upfront, non-refundable, non-contingent licensing fee from DRCN of $500,000.
The company notes that DRCN did not receive or gain access to any aspect of Zelira’s EDCDM technology.
MXC, ECS, NTI and ZLD share prices today:
Related Topics
Related Stories
SUBSCRIBE
Get the latest breaking news and stocks straight to your inbox.
It's free. Unsubscribe whenever you want.
By proceeding, you confirm you understand that we handle personal information in accordance with our Privacy Policy.
